Welcome to the e-CCO Library!

P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Gubbiotti1, B. Barberio1, F. Zingone1, R. D’Incà1, L. Bertani2, A. Ferronato3, M.T. Urbano4, R. Sablich4, E.V. Savarino1

Created: Thursday, 30 January 2020, 10:12 AM
P415: Dose escalation of adalimumab and related prognostic factors in patients with Crohn's disease treated with adalimumab maintenance therapy: A single-centre, five-year cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Nasuno*, H. Tanaka, K. Sugiyama, M. Miyakawa, S. Motoya

Created: Thursday, 21 February 2019, 9:14 AM
P415: Improving food‐related quality of life in Inflammatory Bowel Disease with a novel web-based intervention: a randomised controlled feasibility trial
Year: 2022
Source: ECCO'22
Authors: Cox, S.(1);Wall, C.(2);Clarke, H.(1);Drysdale, C.(1);Czuber-Dochan, W.(3);Lomer, M.(1);Lindsay, J.(4);Whelan, K.(1);
Created: Friday, 11 February 2022, 3:52 PM
P415: Paradoxical onset of Takayasu’s arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agents
Year: 2021
Source: ECCO'21 Virtual
Authors: Matsune, Y.(1);Kouyama, J.(1);Tsuru, Y.(1);Shimizu, K.(1);Asami, S.(1);Matsuyama, S.(1);Katsuki, S.(1);Ishihara, H.(1);Onizawa, R.(1);Shonai, S.(1);Tatsuno, M.(1);Nishikawa, Y.(1);Takeuchi, K.(1);Watanabe, M.(1);Nakamori, Y.(1);Hirayama, A.(1);Toyoda, J.(1);Ikeda, A.(1);Madarame, A.(1);Nishio, M.(1);Ogashiwa, T.(1);Matsubayashi, M.(1);Fujii, A.(1);Kimura, H.(1);Kunisaki, R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P415: Predictive factors of a subsequent ano-perineal abscess in patients with fistulising ano-perineal Crohn’s disease in remission
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Rivière1, A. Malian1, D. Bouchard2, F. Pigot2, M. Eleouet-Kaplan2, C. Favreau-Weltzer2, F. Poullenot1, D. Laharie1

Created: Friday, 22 February 2019, 9:41 AM
P415: Real-world data in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional LISTEN II study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Stallmach, A.(1)*;Schulze, H.(2);Teich, N.(3);Cavlar, T.(4);Jana, K.(4);Henneberger, S.(5);
Created: Friday, 14 July 2023, 11:05 AM
P415: Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. N. W. Chuah*1, P. Delord2, N. Sutiman3, W. F. Leong3, S. C. Kong1, B. Schwender1, P. W. Chan1, H. H. Shim1, E. Salazar1, E. H. Ong4, H. Y. Aw5, J. L. Hartono4, W. C. Lim6, C. Ong7, P. L. Ong8, K. L. Ling1, B. Chowbay2

Created: Friday, 22 February 2019, 9:49 AM
P415: Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Narula N.*1, Borges L.2, Steinhart A.H.3, Colombel J.-F.4

Created: Wednesday, 20 February 2019, 10:36 AM
P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Pai2, J. Popov3, L. Hill4, E. Hartung1, K. Grzywacz5, D. Godin5, L. Thabane6, C. Lee7, W. Khan7, M. Surette2,8,9, P. Moayyedi2,8

Created: Thursday, 30 January 2020, 10:12 AM
P416: Addition of oral antibiotics to mechanical bowel preparation significantly improves anastomotic healing after ileocolic resection for Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Poredska, K.(1);Kunovský, L.(2);Marek, F.(2);Kala, Z.(2);Ivanecká, D.(2);Iesalnieks, I.(3);
Created: Friday, 11 February 2022, 3:52 PM
P416: An online educational portal is effective in improving knowledge regarding reproduction and IBD
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Wierstra1, K. Smith1, J. Bal2, L. Ambrosio2, K. I. Kroeker2, L. Dieleman2, B. Halloran2, R. N. Fedorak2, K.-A. Berga3, V. W. Huang*4

Created: Friday, 22 February 2019, 9:49 AM
P416: Faecal calprotectin can predict mucosal healing in patients with inflammatory bowel diseases treated with vedolizumab: a prospective single-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Bertani*1, L. Ceccarelli2, M. G. Mumolo2, R. Tedeschi1, E. Albano1, G. Tapete1, G. Baiano Svizzero1, N. De Bortoli1, A. Ricchiuti2, M. Bellini1, S. Marchi1, F. Costa2

Created: Friday, 22 February 2019, 9:41 AM
P416: Metabolite measurement for thiopurine therapy in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Sánchez Rodríguez*, R. Ríos León, Á. Flores de Miguel, A. Guerrero García, A. Albillos Martínez, A. López Sanromán

Created: Thursday, 21 February 2019, 9:14 AM
P416: Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Plevris N., Manship T.A., Deekae A., Jones G.R., Noble C.L., Satsangi J., Shand A.G., Arnott I.D., Lees C.W.

Created: Wednesday, 20 February 2019, 10:36 AM
P416: The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Patel, K.V.(1)*;Salmon, P.(2);Marin-Jiménez, I.(3);Thessen, M.(4);Kligys, K.(4);Sharma, D.(4);Sanchez Gonzalez, Y.(4);Kershaw, J.(5);
Created: Friday, 14 July 2023, 11:05 AM
P416: Use of DXA in children with Inflammatory Bowel Disease – a large single centre study
Year: 2021
Source: ECCO'21 Virtual
Authors: Jois, A.(1);Perera, S.(2);Simm, P.(3);Alex, G.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P417 Do ACE inhibitors and angiotensin II receptor blockers improve disease outcomes in inflammatory bowel disease?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. FAIRBRASS1, D. Hoshen1, A.C. Ford1,2, D. Gracie1

Created: Thursday, 30 January 2020, 10:12 AM
P417: 10 years of endoscopic therapy of symptomatic Crohn’s disease stenoses: a retrospective analysis of long-term results
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Aichinger1, K. Rothfuss1, M. Koch1, E. F. Stange1, J. G. Albert1, C. Schäfer1

Created: Friday, 22 February 2019, 9:41 AM
P417: Crohn disease recurrences: Nothing new under the sun?
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Giulii Capponi*, E. Rausa, M. Lotti, F. Bianco, G. Panyor, A. Indriolo, P. Ravelli, L. Campanati

Created: Thursday, 21 February 2019, 9:14 AM
P417: Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wetwittayakhlang, P.(1)*;Karkout, K.(2);Tselekouni, P.(1);Aljabri, R.(1);Bessissow, T.(1);Afif, W.(1);Wild, G.(1);Bitton, A.(1);LakatosPhD, P.L.(3,4);
Created: Friday, 14 July 2023, 11:05 AM